ライフサイエンスコーパス: PPAR

1 PPAR agonists have well-documented anti-inflammatory and

2 PPAR response element (PPRE) activity was measured in PP

3 PPAR-delta activation also reduced HTT-induced neurotoxi

4 PPAR-delta agonists are known to enhance fatty acid meta

5 PPAR-delta overexpression in colonic epithelial cells pr

6 PPAR-gamma agonists, like pioglitazone, appear antiprote

7 PPAR-gamma agonists, such as rosiglitazone, may therefor

8 PPAR-gamma expression in AM was critical for the suppres

9 e (P = 0.026), and 2.25 +/- 0.25 in 15-LOX-1-PPAR-delta-Gut mice (P = 0.0006).

10 ession in colonic epithelial cells (15-LOX-1-PPAR-delta-Gut mice) suppressed these effects: the numbe

11 is required for the induction of PGC-1alpha/PPAR-alpha target genes and oxidative metabolism in resp

12 ic epithelium with 5-amino salicylic acid, a PPAR-gamma (peroxisome proliferator-activated receptor g

13 among people, with 1 SNP allele disrupting a PPAR response element and giving less activation by PPAR

14 ewal potential of these organoid bodies in a PPAR-delta-dependent manner.

15 Even more effective was probucol, a PPAR-activating anti-lipid drug that we show also inhibi

16 e tested the hypothesis that saroglitazar, a PPAR alpha/gamma agonist would improve NASH in the diet-

17 tazone, in a manner inhibited by T0070907, a PPAR-gamma antagonist that also inhibited the ACEA effec

18 t induces Angptl4 and FABP4 expression via a PPAR-dependent pathway.

19 When combined with a PPAR-gammainhibitor GW9662, the effect of DAPA on ZAG wa

20 rat liver caused by dietary treatment with a PPAR-pan (PPAR-alpha, -gamma, and -delta) agonist were p

21 n factor known to interact with and activate PPAR-gamma and NF-kappaB, is suppressed in the glomerula

22 opment of therapeutic strategies to activate PPAR-alpha as well as other PPARs may lead to new therap

23 Notably, HFD- and agonist-activated PPAR-delta signalling endow organoid-initiating capacity

24 Therefore, microbiota-activated PPAR-gamma signaling is a homeostatic pathway that preve

25 lpha-type peroxisome proliferator-activated (PPAR-alpha) receptors; (2) shifted nicotine self-adminis

26 (Tricor), a pan-PPAR agonist that activates PPAR-alpha as well as other PPARs.

27 activated by PPAR-alpha agonists, additional PPAR-alpha is recruited to GR-adjacent sites and presuma

28 l kinase, which are induced by high affinity PPAR agonists.

29 ferator-activated receptor-gamma and -alpha (PPAR-gamma/-alpha) in the NTS and NG in HFD rats were ma

30 isome proliferator-activated receptor alpha (PPAR) target genes, Cpt1alpha, Pgc1alpha, and Ucp1, and

31 isome proliferator-activated receptor alpha (PPAR-alpha) by the PPAR-alpha agonists GW7647 and fenofi

32 isome proliferator-activated receptor alpha (PPAR-alpha) stimulation.

33 isome proliferator activated receptor alpha (PPAR-alpha)(3), and lowered PPAR-alpha activity increase

34 isome proliferator-activated receptor-alpha (PPAR-alpha) agonist that exerts profound anti-inflammato

35 isome proliferator-activated receptor-alpha (PPAR-alpha), and mammalian target of rapamycin (mTOR).

36 FAS, PPAR-alpha, PPAR-gamma, and CB1-R were markedly altered in WT-FF.

37 tor-activated receptors (PPARs), PPAR-alpha, PPAR-gamma, and PPAR-delta.

38 The substrates of FAAH are also PPAR agonists, which explains the PPAR-mediated effects

39 -6, and FIV RNA detection in brain, although PPAR-gamma in glia was increased compared with PBS-treat

40 ective autophagy, restores SIRT1/FoxO3a/AMPK/PPAR-alpha signaling and rectifies metabolic abnormaliti

41 iated by downregulation of SIRT1/FoxO3a/AMPK/PPAR-alpha signaling.

42 naling on SIRT1 activity, and PGC-1alpha and PPAR-alpha target gene expression independent of changes

43 naling (4.47), insulin signaling (3.81), and PPAR pathways (3.75), and downregulated pathways involve

44 phosphorylation, IL-6 promoter activity, and PPAR-delta mRNA and protein expression.

45 lism that were associated with IL6, AMPK and PPAR signal pathways.

46 show that impaired SIRT1, FoxO3a, AMPK, and PPAR-alpha signaling are responsible for autophagy impai

47 ptor gamma in luciferase reporter assay, and PPAR-gamma selective antagonist completely inhibited MDS

48 tory network consisting of GATA3, FOXA1, and PPAR drive luminal cell fate.

49 inical proof-of-concept for combined FXR and PPAR-alpha/delta agonist-based therapies in NASH.

50 ceptors (PPARs), PPAR-alpha, PPAR-gamma, and PPAR-delta.

51 lammatory cascades, namely Wnt, Hedgehog and PPAR pathways, were downregulated.

52 acid metabolism, cholesterol metabolism and PPAR signaling.

53 tor-activated receptor alpha (PPARalpha) and PPAR coactivator-1 alpha (PGC1alpha) signaling with redu

54 esponse to EtOH, while defense responses and PPAR signaling were upregulated.

55 In germ-like cells in vitro, both serum and PPAR agonist induce PPAR activation.

56 gnition and may hold implications for TH and PPAR pharmacology.

57 ons suggest a potential connection of TH and PPAR signaling through overlapping ligand recognition an

58 hways, including LPS, members of the TLR and PPAR families, NF-kappaB, and TNF-related weak inducer o

59 to those of the human, ERs, AR, GR, ERRs and PPARs were more variable with similarities of 60%-100% a

60 ising selective and dual agonism on RXRs and PPARs that may serve as superior pharmacological tools t

61 ovel FAAH inhibitors able to directly act as PPAR agonists and their promising utilization as leads f

62 besogen by PPARgamma transactivation assays, PPAR-driven luciferase induction in vivo, PPARgamma bind

63 ce points to NAAA-regulated PEA signaling at PPAR-alpha as a critical control point for the induction

64 ly, and 4) associated with reduction of both PPAR-gamma and catalase activity, which are reversed by

65 uorescence microscopy to determine that both PPAR mRNA and protein are expressed ubiquitously through

66 y chromatin sites with GR; when activated by PPAR-alpha agonists, additional PPAR-alpha is recruited

67 nteractions due to upregulation of CYP2C8 by PPAR activators.

68 , Hdac3 deletion enhances their induction by PPAR-agonists, and pharmacological HDAC3 inhibition indu

69 enofibrate and GW7647, and were prevented by PPAR-alpha deletion, PPAR-alpha antagonists, and neurost

70 driven growth of urothelium is reversible by PPAR inhibition, supporting PPARs as targetable drivers

71 Mus the complement and coagulation cascades, PPAR signaling pathway and ECM-receptor interactions pre

72 trol and corticosteroid-treated BFU-E cells, PPAR-alpha co-occupies many chromatin sites with GR; whe

73 nking model to distinguish between confirmed PPAR-delta agonists and random molecules.

74 , and were prevented by PPAR-alpha deletion, PPAR-alpha antagonists, and neurosteroid-enzyme inhibito

75 proliferator-activated receptor alpha/delta (PPAR-alpha/delta), respectively.

76 isome proliferator-activated receptor delta (PPAR-delta) interacts with HTT and that mutant HTT repre

77 isome proliferator-activated receptor delta (PPAR-delta) signature in intestinal stem cells and proge

78 isome proliferator-activated receptor-delta (PPAR-delta), which is implicated in bile acid homoeostas

79 Saroglitazar is a dual PPAR-alpha/gamma agonist approved for the treatment of d

80 y pretreatment with an antagonist for either PPAR-alpha (MK886) or cannabinoid CB1 receptors (rimonab

81 iating capacity to progenitors, and enforced PPAR-delta signalling permits these progenitors to form

82 ), a coactivator of the transcription factor PPAR-gamma that controls mitochondrial biogenesis and fu

83 We found that the transcription factor PPAR-gamma was downregulated following IAV infection in

84 elopment depends on the transcription factor PPAR-gamma; however, the environmental cues required for

85 FAS, PPAR-alpha, PPAR-gamma, and CB1-R were markedly altered

86 for the pharmacological target of fibrates (PPAR-alpha), could be used to improve the selection of p

87 14,643, besides being valued as agonists for PPAR, also inhibit hAR.

88 a To determine the mechanism responsible for PPAR-mediated upregulation, we prepared reporter plasmid

89 dence supports a previously unknown role for PPAR-alpha in behavior regulation and suggests new strat

90 These studies revealed a role for PPAR-delta in DC in limiting Th cell priming during EAE.

91 onists were found to be highly selective for PPAR-delta and are structurally different than agonists

92 inding assays, we have mapped the functional PPAR-responsive element to a proximal region from -135 t

93 some proliferation-activated receptor gamma (PPAR) agonist medications, such as antidiabetic glitazon

94 isome proliferator-activated receptor gamma (PPAR-gamma) and glucose transporter 1 (GLUT-1) levels in

95 isome proliferator-activated receptor gamma (PPAR-gamma) expression.

96 isome proliferator-activated receptor gamma (PPAR-gamma) is a downstream target of sildenafil in the

97 isome proliferator-activated receptor gamma (PPAR-gamma) is an important regulator of uteroplacental

98 isome proliferator-activated receptor gamma (PPAR-gamma) protects against hypoxia-associated fetal gr

99 isome proliferator-activated receptor gamma (PPAR-gamma), a ligand-activated nuclear receptor that pr

100 isome proliferator-activated receptor gamma (PPAR-gamma), which is suppressed by HIV-1 replication.

101 isome proliferator-activated receptor gamma (PPAR-gamma)-dependent beta-oxidation of microbiota-deriv

102 isome proliferator-activated receptor gamma (PPAR-gamma).

103 isome proliferator-activated receptor-gamma (PPAR-gamma) agonist, troglitazone, in a manner inhibited

104 isome proliferator-activated receptor-gamma (PPAR-gamma) and sterol regulatory element binding protei

105 isome proliferator-activated receptor-gamma (PPAR-gamma) expression both in vitro and in vivo during

106 isome proliferator-activated receptor-gamma (PPAR-gamma), may counterregulate inflammation in a tissu

107 isome proliferator-activated receptor-gamma (PPAR-gamma), which is induced by exposure to granulocyte

108 isome proliferator-activated receptor-gamma (PPAR-gamma).

109 gulator peroxisome activator receptor-gamma (PPAR-gamma).

110 determined that the Adam10 promoter harbors PPAR response elements; that knockdown of PPARalpha, but

111 TCGA raised the possibility that hyperactive PPAR signaling, either due to PPAR gamma gene amplificat

112 er kinase B1 but fails to normalize impaired PPAR-alpha expression or metabolic abnormalities associa

113 8 in wild-type littermates, 6.67 +/- 0.83 in PPAR-delta-Gut mice (P = 0.026), and 2.25 +/- 0.25 in 15

114 Our results fill critical gaps in PPAR distribution and define novel cell type specificity

115 eated with pioglitazone showed reductions in PPAR-gamma (Ser-273) phosphorylation.

116 No such effect was seen in PPAR-alpha-deficient mice.

117 eraction with the terminal tyrosine found in PPARs.

118 ression of lipid metabolism genes, including PPAR-gamma, by directly methylating their promoters.

119 Increased PPAR-delta transactivation ameliorated mitochondrial dys

120 ion of PPAR-gamma target genes and increased PPAR-gamma DNA-binding activity.

121 iptomic analysis further confirmed increased PPAR-target expression and an anti-inflammatory effect w

122 in vitro, both serum and PPAR agonist induce PPAR activation.

123 equire the mTORC2/AKT/ACLY pathway to induce PPAR-gamma and establish the epigenetic landscape during

124 Microbiota-induced PPAR-gamma signaling also limits the luminal bioavailabi

125 h marked attenuation of phagocytosis-induced PPAR (peroxisome proliferator-activated receptor) expres

126 e antidiabetic drug rosiglitazone, all known PPAR activators.

127 n models of such conditions exceed its known PPAR agonistic profile.

128 receptor alpha (PPAR-alpha)(3), and lowered PPAR-alpha activity increased Notum expression.

129 Our data suggest that targeting macrophage PPAR-gamma may be a promising therapeutic option in the

130 d RSV infections, suggesting that macrophage PPAR-gamma is vital for restricting severe host disease

131 These findings highlight how diet-modulated PPAR-delta activation alters not only the function of in

132 Myeloid PPAR-gamma deficiency resulted in enhanced host morbidit

133 As such, myeloid PPAR-gamma deficiency resulted in impaired inflammation

134 Expression of dominant-negative PPAR-delta in the central nervous system of mice was suf

135 Expression of dominant-negative PPAR-delta specifically in the striatum of medium spiny

136 We highlight the potential of new PPAR ligands with improved efficacy and safety profiles

137 beta-catenin content and normalized nuclear PPAR-gamma in Ob-MSCs.

138 PRE (at nt -769) was essential for obtaining PPAR-mediated transcriptional activation.

139 ide synthase, was elevated in the absence of PPAR-gamma signaling.

140 is study demonstrates that the activation of PPAR-alpha action via fenofibrate leads to neuroprotecti

141 em cells), and pharmacological activation of PPAR-delta recapitulates the effects of a HFD on these c

142 se models of HD, pharmacologic activation of PPAR-delta using the agonist KD3010 improved motor funct

143 Activation of PPAR-gamma partially restored mitochondrial membrane pot

144 on of ZAG in the liver via the activation of PPAR-gamma.

145 tal Lyme arthritis through the activation of PPAR-gamma.

146 Palmitoylethanolamide is an agonist of PPAR-alpha and an important regulator of pain and innate

147 nous administration of synthetic agonists of PPAR-gamma (pioglitazone and rosiglitazone) up-regulates

148 a through cGMP- and PKG-dependent binding of PPAR-gamma to the TRPC6 promoter, which inhibits TRPC6 p

149 rotein response and suggest that blockade of PPAR-gamma (Ser-273) phosphorylation may prevent type 1

150 However, the cell-specific contribution of PPAR-delta to the more severe CNS inflammatory response

151 ported that mice with a global deficiency of PPAR-delta develop an exacerbated course of experimental

152 However, the distribution of PPAR mRNA and protein in brain regions associated with t

153 rough mechanisms involving downregulation of PPAR-gamma and increased activation of NF-kappaB.

154 we explored the anti-inflammatory effect of PPAR-gamma stimulation in vivo in cystic fibrosis transm

155 However, effects of PPAR-alpha on emotional behavior are poorly understood.

156 mmatory processes, whereas the expression of PPAR and insulin target gene transcripts was increased.

157 Profiling expression of PPAR target genes showed upregulation of several genes i

158 This study aims to explore expression of PPAR-gamma and NF-kappaB in placentas of women with peri

159 roups and analyzed to quantify expression of PPAR-gamma and NF-kappaB using real-time polymerase chai

160 DP-glucuronic acid altered the expression of PPAR-gamma target genes and increased PPAR-gamma DNA-bin

161 Expression of PPAR-gamma was downregulated in patients with preeclamps

162 We studied the impact of PPAR-alpha activation on emotional behavior in a mouse m

163 Thus, inhibition of PPAR-gamma and GLUT-1 by E. coli K1 is a novel pathogeni

164 Importantly, inhibition of PPAR-gamma partially prevents the increase in tumorigene

165 us carcinomas are sensitive to inhibition of PPAR-gamma.

166 tudy, we studied the specific involvement of PPAR-delta in myeloid cells during EAE using mice that h

167 trating T cells showed a progressive loss of PPAR-gamma coactivator 1alpha (PGC1alpha), which program

168 Our discovery of the role of PPAR-alpha agonists in stimulating self-renewal of early

169 Our data suggest a critical role of PPAR-gamma expression in lung macrophages in the modulat

170 Stimulation of PPAR-gamma in vivo (rosiglitazone) significantly attenua

171 Identification of 15-LOX-1 suppression of PPAR-delta to inhibit IL-6/STAT3 signaling-driven CAC tu

172 The suppression of PPAR-gamma and GLUT-1 by the bacteria in the brain micro

173 correlated with PEA-induced upregulation of PPAR-alpha, neurosteroidogenic enzyme expression, and no

174 ingitis, and pharmacological upregulation of PPAR-gamma and GLUT-1 levels may provide novel therapeut

175 ols to characterize the molecular effects of PPARs are indispensable.

176 Moreover, the cell type specificity of PPARs in mouse and human brain tissue has yet to be inve

177 c molecular determinants driving activity on PPARs and RXRs.

178 imulation of SCFA receptors GPR41, GPR43, or PPAR, but instead were associated with inhibition of his

179 down or application of antagonists of PKG or PPAR-gamma enhanced TRPC6 expression in podocytes and co

180 sh a central role for HDAC3 in co-ordinating PPAR-regulated lipid oxidation in the intestinal epithel

181 In mouse urothelial organoids, PPAR agonism is sufficient to drive growth-factor-indepe

182 00-fold selectivity for PPARalpha over other PPAR isoforms.

183 gies to activate PPAR-alpha as well as other PPARs may lead to new therapeutic agents to slow or halt

184 t that activates PPAR-alpha as well as other PPARs.

185 caused by dietary treatment with a PPAR-pan (PPAR-alpha, -gamma, and -delta) agonist were profiled by

186 the efficacy of fenofibrate (Tricor), a pan-PPAR agonist that activates PPAR-alpha as well as other

187 hat the administration of bezafibrate, a pan-PPAR agonist, increases the expression of PGC-1alpha and

188 ised as an alternative, notably with the pan-PPAR agonist bezafibrate; clinical trial agents are also

189 Our results suggest that pharmacologic PPAR-gamma activation, via its vasoactive properties, ma

190 Pharmacological PPAR activation in vivo reproduces metabolic dysfunction

191 Our results suggest that pharmacological PPAR-gamma activation is a potential strategy for preven

192 acental insufficiency, and reduced placental PPAR-gamma expression; PIO prevented approximately half

193 d fetal growth restriction reduces placental PPAR-gamma protein expression and placental vascularizat

194 those, 13 molecules were found as potential PPAR-delta agonist leads with EC(50) between 4-19 nM and

195 me proliferator-activated receptors (PPARs), PPAR-alpha, PPAR-gamma, and PPAR-delta.

196 However, prolonged PPAR treatment in animal models has led to adverse side

197 Rats receiving PPAR-gamma antagonists displayed proteinuria and increas

198 creases the activity of the nuclear receptor PPAR-alpha, a PGC-1alpha binding partner, to promote fat

199 The nuclear receptor PPAR-beta/delta (PPARD) has essential roles in fatty aci

200 nsitizers that activate the nuclear receptor PPAR-gamma and have been shown to partially ameliorate a

201 peroxisome proliferator-activated receptor (PPAR) agonist GW501516 (GW), an agent known to boost FAO

202 peroxisome proliferator-activated receptor (PPAR) agonist, relieves cholestasis-associated itch by a

203 peroxisome proliferator-activated receptor (PPAR) alpha and gamma To determine the mechanism respons

204 peroxisome proliferator-activated receptor (PPAR) beta/delta (ST247) and PPARgamma (GW9662).

205 peroxisome proliferator-activated receptor (PPAR) beta/delta deficiency in hepatic FGF21 regulation.

206 peroxisome proliferator-activated receptor (PPAR) beta/delta, a regulator of metabolism, fibrosis, a

207 peroxisome proliferator-activated receptor (PPAR) delta as key regulator of osteoblast metabolism.

208 peroxisome proliferator-activated receptor (PPAR) delta have been validated as molecular targets to

209 peroxisome proliferator-activated receptor (PPAR) family comprises three subtypes: PPARalpha, PPARga

210 peroxisome proliferative-activated receptor (PPAR) family of transcription factors and are critical f

211 peroxisome proliferator-activated receptor (PPAR) gamma agonism reversed TNFalpha-induced insulin re

212 peroxisome proliferator-activated receptor (PPAR) gamma target genes beyond Glut4.

213 peroxisome proliferator-activated receptor (PPAR) gamma, which regulates its activity in the opposit

214 [peroxisome proliferator-activated receptor (PPAR) gamma-coactivator 1alpha], PPARalpha, and catalase

215 Peroxisome Proliferator Activated Receptor (PPAR) pathway would be related to brain development.

216 peroxisome proliferator-activated receptor (PPAR) pathways in the effects of exposure to the germlin

217 peroxisome proliferator-activated receptor (PPAR), and PI3K-Akt-AMPK-mechanistic target of rapamycin

218 peroxisome proliferator-activated receptor (PPAR), respectively, thereby contributing to healthy lon

219 peroxisome proliferator-activated receptor (PPAR)-alpha by the endocannabinoid congener N-palmitoyle

220 peroxisome proliferator-activated receptor (PPAR)-alpha signaling and catabolism of fatty acids (FAs

221 peroxisome proliferator-activated receptor (PPAR)-alpha, carnitine palmitoyl transferase I (CPT1)a,

222 peroxisome proliferator-activated receptor (PPAR)-alpha.

223 Peroxisome proliferator-activated receptor (PPAR)-delta is a fatty acid-activated transcription fact

224 Peroxisome proliferator-activated receptor (PPAR)-gamma activation leads to suppression of productio

225 peroxisome proliferator-activated receptor (PPAR)-gamma ligands have been focused on agonists.

226 peroxisome proliferator-activated receptor (PPAR)-gamma protein; P < 0.05) compared with NW-MSCs.

227 peroxisome proliferator-activated receptor (PPAR)-gamma proteins.

228 peroxisome proliferator-activated receptor (PPAR)alpha and under normal conditions accounts for 70%

229 peroxisome proliferator-activated receptor (PPAR)alpha expression.

230 peroxisome proliferator-activated receptor (PPAR)beta/delta ligand.

231 Peroxisome proliferator-activated receptor (PPAR)gamma activation, through rosiglitazone treatment,

232 peroxisome proliferator-activated receptor (PPAR-gamma/alpha/delta) agonists, sodium glucose cotrans

233 e identify lipid-activated nuclear receptors PPARs as potential mediators of the effects from father

234 peroxisome proliferator-activated receptors (PPARs) and is the receptor for the thiazolidinedione cla

235 Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear hormone receptor famil

236 Peroxisome proliferator-activated receptors (PPARs) are nuclear hormone receptors that act as ligand-

237 Peroxisome proliferator-activated receptors (PPARs) are targets for the treatment of various diseases

238 peroxisome proliferator activated receptors (PPARs) chiral ligands have been designed following the a

239 peroxisome proliferator-activated receptors (PPARs) have been identified as part of the cannabinoid s

240 peroxisome proliferator-activated receptors (PPARs) hold therapeutic potential in neurodegeneration.

241 Peroxisome proliferator-activated receptors (PPARs) regulate both inflammatory and multiple other pat

242 Peroxisome proliferator-activated receptors (PPARs) regulate energy metabolism and hence are therapeu

243 peroxisome proliferator-activated receptors (PPARs), has been generally used to treat hyperlipidemia

244 peroxisome proliferator-activated receptors (PPARs), particularly that of PPARalpha, significantly de

245 peroxisome proliferator-activated receptors (PPARs), PPAR-alpha, PPAR-gamma, and PPAR-delta.

246 peroxisome proliferator-activated receptors (PPARs), PPARgamma, is the receptor for the thiazolidined

247 peroxisome proliferator-activated receptors (PPARs), we investigated the effects of a PPARgamma antag

248 peroxisome proliferator-activated receptors (PPARs), we sought to assess whether HFPO-DA affects andr

249 peroxisome proliferator-activated receptors (PPARs).

250 Peroxisome Proliferator-Activated Receptors (PPARs).

251 peroxisome proliferator-activator receptors [PPARs], and incretins) are modulated by circadian protei

252 rs to terminate inflammation, down-regulates PPAR-delta.

253 pioglitazone and rosiglitazone) up-regulates PPAR-gamma-dependent genes, while inhibiting the activat

254 racts with HTT and that mutant HTT represses PPAR-delta-mediated transactivation.

255 iptional activation of lipogenesis, FXR-RXR, PPAR-alpha mediated lipid oxidation and oxidative stress

256 cer/promoter activity in the context of RXRA/PPAR heterodimers in human bladder cancer cells.

257 Pretreatment with partial or selective PPAR-gamma agonists ameliorate the pathological outcomes

258 evaluate the effectiveness of the selective PPAR-gamma agonist pioglitazone (PIO) for preventing hyp

259 Chromatin immunoprecipitation showed PPAR-gamma binding to the TRPC6 promoter.

260 GM-CSF and intact GM-CSF receptor signaling, PPAR-gamma was not sufficiently upregulated in developin

261 e TRPC6 expression, as did podocyte-specific PPAR-gamma knockout mice, which were more sensitive to a

262 This suggests PPAR gamma pathways may be a fruitful drug target in PD.

263 is reversible by PPAR inhibition, supporting PPARs as targetable drivers of bladder cancer.

264 lecular mechanisms, as well as the synthetic PPAR ligands that are used in the clinic or under develo

265 or cells suggests that the clinically tested PPAR-alpha agonists we used may improve the efficacy of

266 Our results demonstrate that PPAR-gamma activation directly improves beta cell functi

267 te recruiting monocytes, we demonstrate that PPAR-gamma expression in resident AM is likely important

268 Here we identify that PPAR-gamma expression in AM is crucial to suppress pulmo

269 ed from individuals with HD, indicating that PPAR-delta activation may be beneficial in HD and relate

270 signature, which raises the possibility that PPAR agonists may be targeting neurons rather than glia

271 Furthermore, we show that PPAR-gamma was critical for the expression of wound heal

272 Recent evidence suggests that PPAR agonists are attractive therapeutic agents for trea

273 We found that PPARs have unique cell type specificities that are consi

274 The PPAR agonists also activated a 1-kb reporter containing

275 The PPAR-gamma agonist rosiglitazone elicited similar change

276 they share anti-inflammatory activities, the PPAR isotypes distinguish themselves by differential act

277 activated receptor alpha (PPAR-alpha) by the PPAR-alpha agonists GW7647 and fenofibrate synergizes wi

278 These effects were mimicked by the PPAR-alpha synthetic agonists, fenofibrate and GW7647, a

279 H are also PPAR agonists, which explains the PPAR-mediated effects of FAAH inhibitors.

280 Activation of the PPAR (peroxisome proliferator-activated receptor)-fatty

281 ion genes are transcriptional targets of the PPAR family of nuclear receptors, Hdac3 deletion enhance

282 entary and distinct metabolic effects of the PPAR isotypes together with the underlying cellular and

283 eceptor alpha (PPARalpha) is a member of the PPAR nuclear hormone receptor superfamily, which can be

284 Addition of the PPAR-gamma antagonist GW 9662 abrogated the effects of A

285 be partly due to increased expression of the PPAR-gamma co-activator 1-alpha.

286 l the retinoid receptor and particularly the PPAR pathway is involved in progressive hair miniaturiza

287 RA substitution allosterically regulates the PPAR AF2 domain via an aromatic interaction with the ter

288 Although agonists of all three PPARs could activate SULT1C3 transcription, RNA interfer

289 o-lipotoxicity and possibly directly through PPAR-gamma agonism in patients ofT2DM with hypertriglyce

290 hibits TRPC6 expression in podocytes through PPAR-gamma-dependent mechanisms, thereby counteracting p

291 o improvement in insulin sensitivity through PPAR-alpha/gamma agonism, which remains unexplored.

292 de an alternate mechanism that links ATGL to PPAR-alpha signaling.

293 Subsequent docking to PPAR-delta structures was mainly evaluated by geometric

294 at hyperactive PPAR signaling, either due to PPAR gamma gene amplification or RXRA hot-spot mutation

295 and up-regulated gene expression related to PPAR signaling pathways in maternal and fetal livers ([F

296 significant upregulation of genes related to PPAR-mediated lipid metabolism and downregulation of gen

297 ociated with fatty acid/lipid metabolism via PPAR signalling pathway.

298 s is associated with decreased signaling via PPAR and TGF-beta/Smad.

299 In vitro, PPAR-gamma activation with pioglitazone switched macroph

300 ng with TGFbeta1 for receptor binding, while PPAR (peroxisome proliferator-activated receptor)-beta/d

301 expression of GATA3 and FOXA1 cooperate with PPAR activation to drive transdifferentiation of a basal